Please login to the form below

Not currently logged in
Email:
Password:

Kazano

This page shows the latest Kazano news and features for those working in and with pharma, biotech and healthcare.

FDA investigates pancreas risk of diabetes drugs

FDA investigates pancreas risk of diabetes drugs

Newer DPP-4 inhibitors Tradjenta (linagliptin) from Boehringer Ingelheim and Takeda's alogliptin-based medicines (Nesina, Kazano and Oseni) are also affected.

Latest news

  • Takeda gets FDA approval for alogliptin franchise in diabetes Takeda gets FDA approval for alogliptin franchise in diabetes

    Takeda gets FDA approval for alogliptin franchise in diabetes. Comprises Nesina, Oseni and Kazano. ... The US agency approved Takeda's DPP-4 inhibitor Nesina (alogliptin) - along with two fixed-dose combination products Oseni (alogliptin and pioglitazone)

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics